Jun 04, 2020
Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses
Apr 30, 2020
Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer
Apr 22, 2020
Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology
Mar 03, 2020
Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma
Jan 21, 2020
Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy
Jan 08, 2020
Updated Press Release: Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China
Nov 07, 2019
Targovax ASA: Third Quarter 2019 Results
Jun 03, 2019
Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination
May 23, 2019
Targovax to Fully Focus on ONCOS Oncolytic Virus Program
May 09, 2019
Targovax ASA: First Quarter 2019 Results
May 08, 2019
Targovax Announces Completed Enrollment of ONCOS-102 Trial in Mesothelioma
Mar 14, 2019
Targovax Grants Zelluna Immunotherapy an FTO License to Intellectual Property Relating to Mutant Ras T Cell Receptor Technology
Feb 14, 2019
Targovax ASA: Fourth Quarter and Full Year 2018 Results
Jan 17, 2019
Targovax Granted European Patent for Mutant-RAS Neoantigen Platform Lead Products
Dec 12, 2018
Targovax Presents at DNB 9th Annual Nordic Healthcare Conference
Nov 01, 2018
Targovax ASA: Third quarter 2018 Results
Oct 26, 2018
Targovax ASA: Announcement of Third Quarter 2018 Financial Results
Oct 15, 2018
Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer
Oct 12, 2018
Agenda for Targovax Capital Markets Day 15 October 2018, in Oslo, Norway
Oct 04, 2018
Targovax to Host Capital Markets Day 15 October 2018, in Oslo, Norway